Als Disease Models

These models connect molecular changes, including TDP-43 pathology, altered RNA processing, protein aggregation, mitochondrial dysfunction, and neuroinflammation, with the progressive loss of motor neurons. Examining those links helps investigators ask which abnormalities accompany disease onset or progression and how motor neuron vulnerability can be studied experimentally.

Each system offers a different experimental context for examining ALS biology. Patient-derived cells and induced pluripotent stem cell cultures support cellular studies, while organoids and genetically modified animals provide other levels of organization. Comparing results across systems helps researchers recognize the strengths and limitations of each approach.

ALS disease models allow researchers to compare changes associated with genetic and sporadic forms of the disease. This comparison can clarify whether particular molecular abnormalities, patterns of motor neuron vulnerability, or progression-related findings are shared or differ between forms, supporting a more precise interpretation of disease mechanisms.

Model selection depends on the aspect of ALS being examined, such as disease onset, progression, molecular pathology, biomarker discovery, or therapy evaluation. Researchers can use cellular systems, organoids, or genetically modified animals according to the level of biological organization needed, then interpret findings alongside each model’s strengths and limitations.

ALS models support biomarker research by linking measurable molecular changes with disease-related processes and progression. Investigators can examine findings such as TDP-43 pathology, altered RNA processing, protein aggregation, mitochondrial dysfunction, or neuroinflammation, then assess whether these features help track disease biology or distinguish stages of experimental investigation.

Researchers use ALS models to evaluate potential therapies in experimental systems that reproduce selected disease features. Results can show whether an intervention affects relevant molecular abnormalities or processes associated with motor neuron vulnerability. Comparing outcomes across model types also helps identify the strengths and limitations of evidence before further development.